$30.22
+3.63 (+13.65%)
Open$26.98
Previous Close$26.59
Day High$30.23
Day Low$26.95
52W High$30.00
52W Low$3.42
Volume—
Avg Volume883.1K
Market Cap1.43B
P/E Ratio—
EPS$-3.20
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+50.1% upside
Current
$30.22
$30.22
Target
$45.36
$45.36
$37.53
$45.36 avg
$61.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 108.15M | 90.52M | 574.93M |
| Net Income | -151,209,684 | -113,900,833 | 29.33M |
| Profit Margin | -139.8% | -132.8% | 5.1% |
| EBITDA | -141,587,551 | -112,577,982 | 65.79M |
| Free Cash Flow | — | — | 30.48M |
| Rev Growth | +19.5% | +19.5% | -7.8% |
| Debt/Equity | — | — | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |